Inici › Càncer de pròstata › Washington › Seattle
Assaigs clínics de Càncer de pròstata a Seattle, WA
42 estudis de Càncer de pròstata busquen participants en centres de Seattle i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutantFase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- i 1 més
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
ReclutantFase 1
- Swedish Medical Center, Seattle
Precision-Based Genomics in Prostate Cancer
ReclutantEstudi observacional
- University of Washington, Seattle
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Fred Hutchinson Cancer Research Center, Seattle
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
ReclutantFase 1
- Fred Hutchinson Cancer Center, Seattle
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ReclutantFase 2/3
- Fred Hutchinson Cancer Research Center, Seattle
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
ReclutantFase 3
- Swedish Medical Center, Seattle
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
ReclutantFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
ReclutantFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
ReclutantFase 3
- VA Puget Sound Health Care System ( Site 0054), Seattle
- Fred Hutchinson Cancer Center ( Site 0060), Seattle
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
ReclutantEstudi observacional
- University of Washington Medical Center, Seattle
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
ReclutantFase 2
- University of Washington, Seattle
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ReclutantFase 3
- Fred Hutchinson Cancer Center, Seattle
- FHCC at Northwest Hospital, Seattle
- University of Washington Medical Center - Montlake, Seattle
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
ReclutantFase 1
- Investigational Site Number: 400, Seattle
Prostate Active Surveillance Study
ReclutantEstudi observacional
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
ReclutantFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
ReclutantFase 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
ReclutantFase 2
- University of Washington Medical Center, Seattle
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
ReclutantFase 2
- Fred Hutchinson Cancer Center, Seattle
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Fred Hutchinson Cancer Center, Seattle
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ReclutantFase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- i 4 més
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ReclutantFase 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
ReclutantFase 2
- Fred Hutchinson Cancer Center, Seattle
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
ReclutantEstudi observacional
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
ReclutantFase 1
- Fred Hutchinson Cancer Center, Seattle
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
ReclutantFase 1
- Fred Hutchinson Cancer Center, Seattle
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
ReclutantFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
Reclutant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ReclutantFase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- i 4 més
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ReclutantFase 1
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
ReclutantFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
ReclutantFase 2
- VA Puget Sound Health Care System, Seattle
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutantFase 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutantFase 1
- Fred Hutchinson Cancer Center, Seattle
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
ReclutantFase 2
- Swedish Medical Center-Ballard Campus, Seattle
- FHCC South Lake Union, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- i 4 més
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Seattle
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
ReclutantFase 3
- FHCC South Lake Union, Seattle
- FHCC at Northwest Hospital, Seattle
- University of Washington Medical Center - Montlake, Seattle
Assaigs de Càncer de pròstata en altres ciutats
- New York City, NY103 estudis
- Houston, TX76 estudis
- Los Angeles, CA61 estudis
- Boston, MA59 estudis
- St. Louis, MO46 estudis
- Chicago, IL45 estudis
- San Francisco, CA45 estudis
- Philadelphia, PA44 estudis
- Baltimore, MD43 estudis
- Nashville, TN42 estudis
- Washington, DC38 estudis
- Dallas, TX36 estudis
Altres estudis a Seattle
- Càncer de pulmó de cèl·lules no petites53 estudis
- Càncer (tots els tipus)49 estudis
- Leucèmia mieloide aguda40 estudis
- Càncer de mama39 estudis
- Càncer metastàtic39 estudis
- Càncer colorrectal34 estudis
- Càncer de pulmó33 estudis
- Càncer d'ovari30 estudis
- Mieloma múltiple22 estudis
- Síndromes mielodisplàsiques21 estudis
- Leucèmia limfoblàstica aguda21 estudis
- Càncer de bufeta21 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.